Biomimetic apatite formed on cobalt-chromium alloy: A polymer-free carrier for drug eluting stent.
Biomimetic apatite formed on cobalt-chromium alloy: A polymer-free carrier for drug eluting stent.
复制标题
DOI：
10.1016/j.colsurfb.2016.12.021
复制
发表时间：
2017-03
期刊：
影响因子：
--
通讯作者：
Cen Chen;Chenxue Yao;Jingxin Yang;Dandan Luo;X. Kong;Sung-Min Chung;In-Seop Lee
中科院分区：
文献类型：
--
作者：
Cen Chen;Chenxue Yao;Jingxin Yang;Dandan Luo;X. Kong;Sung-Min Chung;In-Seop Lee
在本研究中，首次报道将西罗莫司（SRL）负载在钴铬（Co-Cr）合金上形成的仿生磷灰石中，以抑制支架内再狭窄。制备了两组不同的仿生磷灰石负载SRL组：A组（单层磷灰石/SRL）和B组（双层磷灰石/SRL）。 A 组和 B 组分别显示 SRL 释放长达 40 天和 90 天的双相模式。随着SRL的释放，A组和B组的人动脉平滑肌细胞（HASMC）的附着均受到显着抑制，并且增殖显着下降。值得注意的是，单独的仿生磷灰石也抑制了 SMC 增殖。多孔仿生磷灰石均匀覆盖钴铬支架，无裂纹或织带。球囊膨胀后，仿生磷灰石的完整性足以抵抗分层或破坏。因此，这项研究表明仿生磷灰石是一种有前景的药物载体，可用于支架。
In this study, sirolimus (SRL) was loaded within biomimetic apatite formed on cobalt-chromium (Co-Cr) alloy, which has been reported for the first time, to inhibit the in-stent restenosis. Two different groups of loading SRL within biomimetic apatite were prepared: Group A (mono-layer of apatite/SRL) and Group B (bi-layer of apatite/SRL). Group A and Group B showed the biphasic pattern of SRL release up to 40 and 90 days, respectively. The attachment of human artery smooth muscle cell (HASMC) for both Group A and Group B was significantly inhibited, and proliferation dramatically decreased with the release of SRL. Noteworthily, biomimetic apatite alone also suppressed the SMC proliferation. The porous biomimetic apatite uniformly covered Co-Cr stent without crack or webbings. After balloon expansion, the integrity of biomimetic apatite was sufficient to resist delamination or destruction. Thus, this study demonstrated that biomimetic apatite is a promising drug carrier for potential use in stents.